DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Hemodynamic Effects of Spironolactone in Patients With Heart Failure

Information source: University of Toledo Health Science Campus
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Congestive Heart Failure

Intervention: Spironolactone (Drug)

Phase: N/A

Status: Completed

Sponsored by: University of Toledo Health Science Campus

Summary

To determine if the beneficial effect of spironolactone in patients with congestive heart failure is in part due to its intrinsic inotropic action. Randomized, two group placebo controlled, single blind study.

Clinical Details

Official title: Hemodynamic Effects of Spironolactone in Patients With Heart Failure

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Echocardiogram

Measure of Kidney function and potassium levels

Eligibility

Minimum age: 21 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- CHF

- 21 - 80 years

- Serum creatinine < 2 mg/dL

- Serum potassium 2. 7 - 4. 5 mg/dL measured within past 4 weeks

Exclusion Criteria:

- Less than 21 years

- Pregnancy

Locations and Contacts

Medical University of Ohio, Toledo, Ohio 43614, United States
Additional Information

Starting date: February 2003
Last updated: December 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017